Aura Biosciences (AURA) vs Bambusa Therapeutics (BBTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Bambusa Therapeutics is the larger company by market cap ($815.1 million vs $715.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AURA | BBTX |
|---|---|---|
| Share price | $6.87 | $16.00 |
| Market cap | $714.99M | $815.08M |
| 1-day change | -1.58% | +2.89% |
| YTD return | +26.06% | — |
| 1-year return | +26.29% | — |
| 5-year return | -69.63% | — |
| EPS (TTM) | $-1.59 | $-1.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-106.19M | — |
| 52-week high | $9.54 | $17.65 |
| 52-week low | $4.73 | $13.60 |
| Distance from 52-week high | -27.95% | -9.35% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +141.63% | — |
| Average volume | 847.22K | 359.41K |
| Shares outstanding | 104.07M | 50.94M |
| Employees | 113 | 26 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aura Biosciences
AURA stock →Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 113 employees
About Bambusa Therapeutics
BBTX stock →Bambusa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops long-acting bispecific antibodies for the treatment of immunological and inflammatory disorders. The company develops BBT001 for Type 2 inflammatory dermatological conditions, including atopic dermatitis, chronic spontaneous urticaria, and prurigo nodularis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 26 employees
AURA vs BBTX FAQ
Which is bigger, Aura Biosciences or Bambusa Therapeutics?
Bambusa Therapeutics (BBTX) is larger, with a market capitalization of $815.08M compared with $714.99M for Aura Biosciences (AURA).
Are Aura Biosciences and Bambusa Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.